News Image

Why NYSE:PFE is a Top Pick for Dividend Investors.

By Mill Chart

Last update: Sep 21, 2023

Our stock screener has singled out PFIZER INC (NYSE:PFE) as a promising choice for dividend investors. NYSE:PFE not only scores well in profitability, solvency, and liquidity but also offers a decent dividend. We'll explore this further.

Assessing Dividend for NYSE:PFE

ChartMill assigns a Dividend Rating to every stock. This score ranges from 0 to 10 and evaluates the different dividend aspects, including the yield, the growth and sustainability. NYSE:PFE scores a 8 out of 10:

  • With a Yearly Dividend Yield of 4.80%, PFE is a good candidate for dividend investing.
  • Compared to an average industry Dividend Yield of 15.34, PFE pays a better dividend. On top of this PFE pays more dividend than 97.10% of the companies listed in the same industry.
  • PFE's Dividend Yield is rather good when compared to the S&P500 average which is at 2.35.
  • PFE has been paying a dividend for at least 10 years, so it has a reliable track record.
  • PFE has not decreased their dividend for at least 10 years, which is a reliable track record.
  • Unpacking NYSE:PFE's Health Rating

    ChartMill employs a unique Health Rating system for all stocks. This rating, ranging from 0 to 10, is determined by analyzing various liquidity and solvency ratios. For NYSE:PFE, the assigned 5 for health provides valuable insights:

  • PFE has a Altman-Z score of 2.69. This is in the better half of the industry: PFE outperforms 73.43% of its industry peers.
  • PFE's Debt to FCF ratio of 6.13 is amongst the best of the industry. PFE outperforms 84.54% of its industry peers.
  • A Current Ratio of 2.12 indicates that PFE has no problem at all paying its short term obligations.
  • Understanding NYSE:PFE's Profitability

    ChartMill assigns a Profitability Rating to every stock. This score ranges from 0 to 10 and evaluates the different profitability ratios and margins, both absolutely, but also relative to the industry peers. NYSE:PFE scores a 8 out of 10:

  • Looking at the Return On Assets, with a value of 9.75%, PFE belongs to the top of the industry, outperforming 90.82% of the companies in the same industry.
  • With an excellent Return On Equity value of 21.68%, PFE belongs to the best of the industry, outperforming 91.79% of the companies in the same industry.
  • PFE has a better Return On Invested Capital (11.96%) than 89.86% of its industry peers.
  • The 3 year average ROIC (16.16%) for PFE is well above the current ROIC(11.96%). The reason for the recent decline needs to be investigated.
  • Looking at the Profit Margin, with a value of 27.55%, PFE belongs to the top of the industry, outperforming 94.69% of the companies in the same industry.
  • PFE has a better Operating Margin (31.21%) than 95.65% of its industry peers.
  • In the last couple of years the Operating Margin of PFE has grown nicely.
  • With a decent Gross Margin value of 68.78%, PFE is doing good in the industry, outperforming 73.43% of the companies in the same industry.
  • Every day, new Best Dividend stocks can be found on ChartMill in our Best Dividend screener.

    For an up to date full fundamental analysis you can check the fundamental report of PFE


    This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.



    NYSE:PFE (12/8/2023, 7:09:48 PM)

    Premarket: 28.9 +0.12 (+0.42%)


    +0.15 (+0.52%)

    PFE News

    News Imagea day ago - Pfizer Inc.Marstacimab Phase 3 Data Presented at ASH 2023 Demonstrate Significant Bleed Reduction in Hemophilia A and B
    News Image2 days ago - The Motley Fool3 Dividend Stocks Trading at 52-Week Lows

    All three of these companies have seen brighter days.

    News Image2 days ago - The Motley FoolIs Pfizer Stock a Buy Now?

    Pfizer's stock recently hit a new 52-week low as the bad news continues for the pharma giant.

    News Image2 days ago - InvestorPlace3 Blue-Chip Stocks Set to Make a Comeback in 2024

    These are the blue-chip stocks to buy as they represent quality companies with a steady growth outlook and promising cash flow growth.

    News Image3 days ago - The Motley FoolPfizer's Latest Ozempic Competitor Just Flopped (Again). Is the Stock Still a Buy?

    It's already planning to get back on the horse and make another attempt.

    News Image3 days ago - Seeking AlphaPfizer receives EU approval for multiple myeloma therapy (NYSE:PFE)

    Pfizer (PFE) has received conditional approval for its immunotherapy elrexfio in the treatment of multiple myeloma.

    News Image3 days ago - Pfizer Inc.European Commission Approves Pfizer’s ELREXFIO® for Relapsed and Refractory Multiple Myeloma
    News Image3 days ago - InvestorPlace7 Tech Stocks to Light Up Your Portfolio This Holiday Season

    Are you looking for the best tech stocks this holiday season? Here are seven stocks to light up your portfolio this holiday season.

    News Image3 days ago - InvestorPlace7 F-Rated Stocks to Sell in December

    If you’re holding F-rated stocks to sell, it may be too late to salvage 2023, but you can still get back on track toward achieving your goals.

    News Image4 days ago - BusinessInsiderVaccine Player Vaxcyte Can Potentially Disrupt Pfizer's 20-Plus-Year Near Monopoly, Says Analyst

    Mizuho Securities initiated coverage on Vaxcyte Inc (NASDAQ: PCVX), a vaccine company targeting bacterial infectious diseases (primarily for disease prevention). 

    News Image4 days ago - Yahoo FinanceBain scores over tenfold return with $8.7 billion Cerevel sale

    Private equity firm Bain Capital stands to make more than 10 times the $250 million it invested in Cerevel Therapeutics Holdings Inc following the neurology-focused drug developer's $8.7 billion sale to AbbVie Inc, according to regulatory filings. Boston-based Bain committed $350 million in 2018 to carve Cambridge, Massachusetts-based Cerevel out of Pfizer Inc, but only $250 million of that was drawn, the filings show. The deal with AbbVie, announced on Tuesday, now values Bain's 36.5% stake in Cerevel at about $2.7 billion.

    News Image4 days ago - SBWireNeuropsychiatric Disorders and Treatment Market Projected to Show Strong Growth: Astrazeneca, AviadoBio, Astellas Pharma

    Get an extensive Neuropsychiatric Disorders And Treatment Market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry.

    PFE Links
    Follow us for more